In the past week, TWST stock has gone up by 3.93%, with a monthly decline of -2.92% and a quarterly plunge of -1.36%. The volatility ratio for the week is 5.65%, and the volatility levels for the last 30 days are 5.33% for Twist Bioscience Corp The simple moving average for the last 20 days is 3.07% for TWST’s stock, with a simple moving average of 15.38% for the last 200 days.
Is It Worth Investing in Twist Bioscience Corp (NASDAQ: TWST) Right Now?
TWST has 36-month beta value of 1.63. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for TWST is 55.30M, and currently, short sellers hold a 22.16% ratio of that float. The average trading volume of TWST on May 02, 2024 was 902.27K shares.
TWST) stock’s latest price update
Twist Bioscience Corp (NASDAQ: TWST)’s stock price has gone rise by 2.34 in comparison to its previous close of 31.23, however, the company has experienced a 3.93% increase in its stock price over the last five trading days. InvestorPlace reported 2024-04-30 that Biotech stocks offer the opportunity to invest in life-saving treatments and drugs. So not only can you make massive gains but you are also investing in the advancement of modern medicine.
Analysts’ Opinion of TWST
Many brokerage firms have already submitted their reports for TWST stocks, with Goldman repeating the rating for TWST by listing it as a “Buy.” The predicted price for TWST in the upcoming period, according to Goldman is $45 based on the research report published on January 17, 2024 of the current year 2024.
Berenberg, on the other hand, stated in their research note that they expect to see TWST reach a price target of $27. The rating they have provided for TWST stocks is “Buy” according to the report published on September 27th, 2023.
Scotiabank gave a rating of “Sector Outperform” to TWST, setting the target price at $33 in the report published on January 05th of the previous year.
TWST Trading at -6.91% from the 50-Day Moving Average
After a stumble in the market that brought TWST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.04% of loss for the given period.
Volatility was left at 5.33%, however, over the last 30 days, the volatility rate increased by 5.65%, as shares sank -4.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.11% lower at present.
During the last 5 trading sessions, TWST rose by +3.93%, which changed the moving average for the period of 200-days by +32.23% in comparison to the 20-day moving average, which settled at $30.94. In addition, Twist Bioscience Corp saw -13.29% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TWST starting from Finn Patrick John, who sale 2,174 shares at the price of $30.12 back on Apr 23 ’24. After this action, Finn Patrick John now owns 176,206 shares of Twist Bioscience Corp, valued at $65,483 using the latest closing price.
Laponis Adam, the Chief Financial Officer of Twist Bioscience Corp, sale 556 shares at $33.16 during a trade that took place back on Apr 09 ’24, which means that Laponis Adam is holding 74,444 shares at $18,434 based on the most recent closing price.
Stock Fundamentals for TWST
Current profitability levels for the company are sitting at:
- -0.84 for the present operating margin
- 0.36 for the gross margin
The net margin for Twist Bioscience Corp stands at -0.78. The total capital return value is set at -0.33. Equity return is now at value -30.80, with -25.06 for asset returns.
Based on Twist Bioscience Corp (TWST), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -1.21. The debt to equity ratio resting at 0.16. The interest coverage ratio of the stock is -55175.5.
Currently, EBITDA for the company is -193.21 million with net debt to EBITDA at 0.96. When we switch over and look at the enterprise to sales, we see a ratio of 6.3. The receivables turnover for the company is 7.42for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.98.
Conclusion
To put it simply, Twist Bioscience Corp (TWST) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
